Recommended IV Bumetanide Regimen
For a patient on oral bumetanide 2 mg twice daily (4 mg total daily), convert to IV bumetanide at 2-10 mg IV once to three times daily, starting with at least 2-4 mg IV as the initial dose. 1
Conversion Rationale
The 2019 ACC Expert Consensus provides explicit guidance: for patients already receiving loop diuretics prior to admission, the oral dose should be changed to an intravenous dose of 1-2.5 times the home dose 1. Given your patient's home regimen of 4 mg oral bumetanide daily:
- Minimum starting IV dose: 4 mg × 1 = 4 mg IV daily
- Maximum starting IV dose: 4 mg × 2.5 = 10 mg IV daily
- Practical approach: Start with 2 mg IV every 8-12 hours (6-8 mg total daily), which represents approximately 1.5-2× the oral dose
Dosing Options
You have two administration strategies 1:
Intermittent Bolus Dosing (Preferred Initial Approach)
- 0.5-4 mg IV once to three times daily (maximum 5 mg/dose)
- Administer over 1-2 minutes 2
- If inadequate response, give second or third dose at 2-3 hour intervals
- Do not exceed 10 mg daily 2
Continuous Infusion (For Refractory Cases)
- 0.5-2 mg/hour IV infusion (maximum 4 mg/hour) 1
- Consider if intermittent dosing fails to achieve adequate decongestion
Monitoring the Response
Assess diuretic adequacy at 2 hours - this timeframe is sufficient and reliable 3:
- Target urine output: >100-150 mL/hour in first 6 hours 4
- Target spot urine sodium: >50-70 mmol/L at 2 hours 4
- Daily weight loss goal: 0.5-1.5 kg per day 4
If these targets are not met, double the dose for the next administration 3.
Important Clinical Considerations
Bioavailability Advantage
Bumetanide has superior oral bioavailability (80-90%) compared to furosemide (50%) 5, 6. This means the oral-to-IV conversion ratio for bumetanide is closer to 1:1 than furosemide's 1:2.5 ratio. However, guidelines still recommend the 1-2.5× multiplier for safety and to ensure adequate diuresis in the acute setting 1.
Daily Monitoring Requirements
- Electrolytes (especially potassium, sodium)
- Serum creatinine and BUN
- Daily weights
- Intake and output
- Symptoms and clinical exam
Common Pitfall
Expect mild creatinine elevation during effective decongestion - this typically returns to baseline after discharge and is not associated with worse outcomes 1. Don't prematurely reduce diuretic dosing based solely on rising creatinine if the patient is still congested.
Escalation Strategy
If congestion persists after 24-48 hours of optimized IV bumetanide:
- Add thiazide-type diuretic (e.g., metolazone 2.5-5 mg orally) 7, 1
- Consider adding acetazolamide 4
- Consider switching to continuous infusion if using intermittent dosing 1
Transition Back to Oral
Once adequate decongestion is achieved and the patient is hemodynamically stable, transition back to oral bumetanide 1. The discharge oral dose should be adjusted based on the total IV dose required to achieve decongestion.